REL and neoplasm: Tumor models of other cancers have shown that loss of Treg expression of c-Rel, but not p65 slowed melanoma growth as did chemical inhibition of c-Rel function, with targeting of c-Rel also enhancing checkpoint-targeting immunotherapy for this cancer [227].